OTC Markets OTCPK - Delayed Quote USD

WuXi Biologics (Cayman) Inc. (WXIBF)

Compare

2.1900

+0.0200

(+0.92%)

As of 12:22:32 PM EST. Market Open.

Currency in USD All numbers in thousands

Download

Breakdown

TTM

12/31/2023

12/31/2022

12/31/2021

12/31/2020

Total Revenue

17,034,255.0000

15,268,660.0000

10,290,050.0000

5,612,384.0000

Cost of Revenue

10,206,354.0000

8,544,646.0000

5,461,153.0000

3,079,418.0000

Gross Profit

6,827,901.0000

6,724,014.0000

4,828,897.0000

2,532,966.0000

Operating Expense

2,377,704.0000

1,925,659.0000

1,364,232.0000

771,431.0000

Operating Income

4,450,197.0000

4,798,355.0000

3,464,665.0000

1,761,535.0000

Net Non Operating Interest Income Expense

60,690.0000

43,093.0000

18,835.0000

38,132.0000

Pretax Income

4,173,803.0000

5,357,771.0000

3,993,119.0000

1,965,760.0000

Tax Provision

603,179.0000

807,865.0000

484,538.0000

273,066.0000

Net Income Common Stockholders

3,399,729.0000

4,420,286.0000

3,388,478.0000

1,688,886.0000

Average Dilution Earnings

-39,505.0000

Diluted NI Available to Com Stockholders

3,360,224.0000

4,420,286.0000

3,388,478.0000

1,688,886.0000

Basic EPS

0.82

1.06

0.81

0.43

Diluted EPS

0.77

1.01

0.77

0.40

Basic Average Shares

4,163,542.5670

4,172,735.8930

4,173,681.1270

3,952,963.5290

Diluted Average Shares

4,348,874.4780

4,375,907.8930

4,421,796.9340

4,209,169.3360

Total Expenses

12,584,058.0000

10,470,305.0000

6,825,385.0000

3,850,849.0000

Net Income from Continuing & Discontinued Operation

3,399,729.0000

4,420,286.0000

3,388,478.0000

1,688,886.0000

Normalized Income

3,572,812.9320

5,050,448.3600

3,234,377.8730

1,473,290.8814

Interest Income

219,178.0000

107,475.0000

58,026.0000

80,864.0000

Interest Expense

158,488.0000

64,382.0000

39,191.0000

42,732.0000

Net Interest Income

60,690.0000

43,093.0000

18,835.0000

38,132.0000

EBIT

4,332,291.0000

5,422,153.0000

4,032,310.0000

2,008,492.0000

EBITDA

5,501,667.0000

6,222,827.0000

4,514,093.0000

2,311,501.0000

Reconciled Cost of Revenue

10,206,354.0000

8,544,646.0000

5,461,153.0000

3,079,418.0000

Reconciled Depreciation

1,169,376.0000

800,674.0000

481,783.0000

303,009.0000

Net Income from Continuing Operation Net Minority Interest

3,399,729.0000

4,420,286.0000

3,388,478.0000

1,688,886.0000

Total Unusual Items Excluding Goodwill

-203,868.0000

-737,032.0000

175,313.0000

250,375.0000

Total Unusual Items

-203,868.0000

-737,032.0000

175,313.0000

250,375.0000

Normalized EBITDA

5,705,535.0000

6,959,859.0000

4,338,780.0000

2,061,126.0000

Tax Rate for Calcs

0.0002

0.0001

Tax Effect of Unusual Items

-30,784.0680

-106,869.6400

21,212.8730

34,779.8814

12/31/2020 - 1/30/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

4RD.DU Maat Pharma SA

8.80

+6.54%

GNMSF Genmab A/S

220.81

0.00%

CMXHF CSL Limited

176.78

0.00%

IVBIY Innovent Biologics Inc.

19.15

0.00%

UCBJF UCB SA

194.85

0.00%

UCBJY UCB SA

100.40

+0.23%

4RD.F MaaT Pharma SA

8.34

-4.79%

KANT Kineta, Inc.

0.3901

-7.12%

CSLLY CSL Limited

87.27

-2.60%

GOVXW GeoVax Labs, Inc.

0.1462

-8.62%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

WuXi Biologics (Cayman) Inc. (WXIBF)

Upgrade to begin using 40 years of financial statements and get so much more.

Related Tickers